{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:05:00Z","timestamp":1760101500834,"version":"3.37.3"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-024-08419-9","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T15:03:13Z","timestamp":1725289393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Collecting and reporting adverse events in low-income settings\u2014perspectives from vaccine trials in the Gambia"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8597-5975","authenticated-orcid":false,"given":"Andrew Ayi-Ashong","family":"Bruce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ama-Onyebuchi","family":"Umesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adedapo","family":"Bashorun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Ochoge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Yisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolapo","family":"Obayemi-Ajiboye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Futa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Njie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selasi","family":"Asase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Modou Bella","family":"Jallow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Kotei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Affleck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olubunmi Abiola","family":"Olubiyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamin B.","family":"Jarju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madi","family":"Kanyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baba","family":"Danso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armel","family":"Zemsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"8419_CR1","doi-asserted-by":"crossref","unstructured":"Hansson SO. Why and for what are clinical trials the gold standard? Scandinavian Journal of Public Health. 2014;42(13_suppl):41\u20138.","DOI":"10.1177\/1403494813516712"},{"key":"8419_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-3-031-19719-2_3","volume-title":"Healthcare and disease burden in Africa: the impact of socioeconomic factors on public health","author":"I Niohuru","year":"2023","unstructured":"Niohuru I. Disease Burden and Mortality. In: Niohuru I, editor. Healthcare and disease burden in Africa: the impact of socioeconomic factors on public health. Cham: Springer International Publishing; 2023. p. 35\u201385."},{"key":"8419_CR3","unstructured":"Worldometer. Africa population [11 Jan 2024]. Available from: https:\/\/www.worldometers.info\/world-population\/africa-population\/#:~:text=Africa%20Population%20(LIVE)&text=Africa%20population%20is%20equivalent%20to,%22)%2C%20ordered%20by%20population."},{"issue":"9","key":"8419_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008932","volume":"5","author":"RF Viergever","year":"2015","unstructured":"Viergever RF, Li K. Trends in global clinical trial registration: an analysis of numbers of registered clinical trials in different parts of the world from 2004 to 2013. BMJ Open. 2015;5(9): e008932.","journal-title":"BMJ Open"},{"issue":"6","key":"8419_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/qjmed\/hcab010","volume":"114","author":"SD Taylor-Robinson","year":"2021","unstructured":"Taylor-Robinson SD, Spearman CW, Suliman AAA. Why is there a paucity of clinical trials in Africa? QJM. 2021;114(6):357\u20138.","journal-title":"QJM"},{"issue":"38","key":"8419_CR6","doi-asserted-by":"publisher","first-page":"24155","DOI":"10.1021\/acsomega.0c04327","volume":"5","author":"E Marincola","year":"2020","unstructured":"Marincola E, Kariuki T. Quality research in Africa and why it is important. ACS Omega. 2020;5(38):24155\u20137.","journal-title":"ACS Omega"},{"issue":"20","key":"8419_CR7","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","volume":"365","author":"ST Agnandji","year":"2011","unstructured":"Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al. First results of phase 3 trial of RTS, S\/AS01 malaria vaccine in African children. N Engl J Med. 2011;365(20):1863\u201375.","journal-title":"N Engl J Med"},{"issue":"6","key":"8419_CR8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/tmi.13876","volume":"28","author":"G Sulis","year":"2023","unstructured":"Sulis G, Peebles A, Basta NE. Lassa fever vaccine candidates: a scoping review of vaccine clinical trials. Trop Med Int Health. 2023;28(6):420\u201331.","journal-title":"Trop Med Int Health"},{"key":"8419_CR9","unstructured":"Organization WH. World malaria report 2023: World Health Organization; 2023."},{"issue":"2","key":"8419_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.tig.2020.11.005","volume":"37","author":"C Fortes-Lima","year":"2021","unstructured":"Fortes-Lima C, Schlebusch C. Closing the gaps in genomic research. Trends Genet. 2021;37(2):104\u20136.","journal-title":"Trends Genet"},{"key":"8419_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1146\/annurev.genom.9.081307.164258","volume":"9","author":"MC Campbell","year":"2008","unstructured":"Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet. 2008;9:403\u201333.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"1","key":"8419_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/mi.2014.114","volume":"8","author":"E Clarke","year":"2015","unstructured":"Clarke E, Desselberger U. Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. Mucosal Immunol. 2015;8(1):1\u201317.","journal-title":"Mucosal Immunol"},{"key":"8419_CR13","unstructured":"Africa faces 470 million COVID-19 vaccine shortfall in 2021 WHO Africa [30 March 2024]. Available from: https:\/\/www.afro.who.int\/news\/africa-faces-470-million-covid-19-vaccine-shortfall-2021."},{"key":"8419_CR14","unstructured":"A Breakthrough for the African Vaccine Manufacturing Africa CDC [20 Mar 2024]. Available from: https:\/\/africacdc.org\/news-item\/a-breakthrough-for-the-african-vaccine-manufacturing\/#:~:text=The%20goal%20of%20the%20PAVM,30%20per%20cent%20by%202030."},{"key":"8419_CR15","unstructured":"Declaration of Helsinki. http:\/\/www.med or jp\/wma\/helsinki02_j html. 1964;World Medical Association."},{"key":"8419_CR16","unstructured":"Integrated addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2) International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) [27 Feb 2024]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf."},{"issue":"2","key":"8419_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00002018-199410020-00001","volume":"10","author":"IR Edwards","year":"1994","unstructured":"Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf. 1994;10(2):93\u2013102.","journal-title":"Drug Saf"},{"key":"8419_CR18","volume-title":"Handbook for good clinical research practice (GCP): guidance for implementation","author":"World Health Organization","year":"2005","unstructured":"World Health Organization. Handbook for good clinical research practice (GCP): guidance for implementation. Geneva: World Health Organization; 2005."},{"key":"8419_CR19","doi-asserted-by":"crossref","unstructured":"Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, et al. Safety of COVID-19 vaccines. J Med Virol. 2021;93(12):6588\u201394.","DOI":"10.1002\/jmv.27214"},{"issue":"1","key":"8419_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/pharmaceutics5010094","volume":"5","author":"B Yao","year":"2013","unstructured":"Yao B, Zhu L, Jiang Q, Xia HA. Safety monitoring in clinical trials. Pharmaceutics. 2013;5(1):94\u2013106.","journal-title":"Pharmaceutics"},{"issue":"8","key":"8419_CR21","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.4161\/hv.24961","volume":"9","author":"S Ozawa","year":"2013","unstructured":"Ozawa S, Stack ML. Public trust and vaccine acceptance\u2013international perspectives. Hum Vaccin Immunother. 2013;9(8):1774\u20138.","journal-title":"Hum Vaccin Immunother"},{"key":"8419_CR22","unstructured":"World Bank. GDP per capita (current US$) - Gambia, The [30 Mar 2024]. Available from: https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?locations=GM."},{"issue":"7","key":"8419_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219919","volume":"14","author":"AJ Rerimoi","year":"2019","unstructured":"Rerimoi AJ, Jasseh M, Agbla SC, Reniers G, Roca A, Tim\u00e6us IM. Under-five mortality in The Gambia: comparison of the results of the first demographic and health survey with those from existing inquiries. PLoS ONE. 2019;14(7): e0219919.","journal-title":"PLoS ONE"},{"key":"8419_CR24","unstructured":"UNICEF. Gambia (GMB) - Demographics, Health & Infant Mortality - UNICEF DATA [19 March 2024]. Available from: https:\/\/data.unicef.org\/country\/gmb\/."},{"key":"8419_CR25","unstructured":"World Bank. Mortality rate, under-5 (per 1,000 live births) - high income [27 March 2024]. Available from: https:\/\/data.worldbank.org\/indicator\/SH.DYN.MORT?locations=XD."},{"issue":"9730","key":"8419_CR26","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/S0140-6736(10)60549-1","volume":"375","author":"RE Black","year":"2010","unstructured":"Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. The Lancet. 2010;375(9730):1969\u201387.","journal-title":"The Lancet"},{"issue":"1","key":"8419_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.31586\/gjeid.2022.247","volume":"2","author":"AAA Barrow","year":"2022","unstructured":"Barrow AAA, Azubuike PC, Cham D. Prevalence and determinants of acute respiratory infections among children under five years in rural settings of the Gambia: evidence from a national survey. GJEID. 2022;2(1):23\u201332.","journal-title":"GJEID"},{"issue":"1 Suppl","key":"8419_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4269\/ajtmh.12-0751","volume":"89","author":"D Saha","year":"2013","unstructured":"Saha D, Akinsola A, Sharples K, Adeyemi MO, Antonio M, Imran S, et al. Health Care Utilization and Attitudes Survey: understanding diarrheal disease in rural Gambia. Am J Trop Med Hyg. 2013;89(1 Suppl):13\u201320.","journal-title":"Am J Trop Med Hyg"},{"key":"8419_CR29","unstructured":"Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;399(10341):2129\u201354."},{"key":"8419_CR30","unstructured":"World Bank. Adult literacy in the Gambia is lower among women than among men (2021) 2021 [16 Jan 2024]. Available from: https:\/\/genderdata.worldbank.org\/countries\/gambia-the\/."},{"key":"8419_CR31","unstructured":"National Review Report on Implementation of the Beijing Declaration and Platform for Action (BPFA) +25 UN Women [16 Jan 2024]. Available from: https:\/\/www.unwomen.org\/sites\/default\/files\/Headquarters\/Attachments\/Sections\/CSW\/64\/National-reviews\/Gambia.pdf."},{"issue":"3","key":"8419_CR32","first-page":"329","volume":"3","author":"K Juffermans","year":"2009","unstructured":"Juffermans K, McGlynn C. A sociolinguistic profile of The Gambia. Socioling Stud. 2009;3(3):329\u201355.","journal-title":"Socioling Stud"},{"key":"8419_CR33","unstructured":"World Bank. Individuals using the Internet (% of population) - Gambia, The The World Bank [24 Feb 2024]. Available from: https:\/\/data.worldbank.org\/indicator\/IT.NET.USER.ZS?locations=GM."},{"issue":"1","key":"8419_CR34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1542\/peds.86.1.102","volume":"86","author":"H Campbell","year":"1990","unstructured":"Campbell H, Byass P, Ahonkhai VI, Vella PP, Greenwood BM. Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants. Pediatrics. 1990;86(1):102\u20137.","journal-title":"Pediatrics"},{"issue":"3","key":"8419_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/02724936.1994.11747715","volume":"14","author":"EK Mulholland","year":"1994","unstructured":"Mulholland EK, Byass P, Campbell H, Fritzell B, Greenwood AM, Todd J, Greenwood BM. The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants. Ann Trop Paediatr. 1994;14(3):183\u20138.","journal-title":"Ann Trop Paediatr"},{"issue":"9060","key":"8419_CR36","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S0140-6736(96)09267-7","volume":"349","author":"K Mulholland","year":"1997","unstructured":"Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet. 1997;349(9060):1191\u20137.","journal-title":"Lancet"},{"issue":"4","key":"8419_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/00006454-199604000-00010","volume":"15","author":"A Leach","year":"1996","unstructured":"Leach A, Ceesay SJ, Banya WA, Greenwood BM. Pilot trial of a pentavalent pneumococcal polysaccharide\/protein conjugate vaccine in Gambian infants. Pediatr Infect Dis J. 1996;15(4):333\u20139.","journal-title":"Pediatr Infect Dis J"},{"issue":"9465","key":"8419_CR38","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S0140-6736(05)71876-6","volume":"365","author":"FT Cutts","year":"2005","unstructured":"Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365(9465):1139\u201346.","journal-title":"Lancet"},{"issue":"9297","key":"8419_CR39","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(01)06957-4","volume":"358","author":"KA Bojang","year":"2001","unstructured":"Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, et al. Efficacy of RTS, S\/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomised trial. Lancet. 2001;358(9297):1927\u201334.","journal-title":"Lancet"},{"issue":"6","key":"8419_CR40","doi-asserted-by":"publisher","first-page":"865","DOI":"10.4269\/ajtmh.1999.61.865","volume":"61","author":"JF Doherty","year":"1999","unstructured":"Doherty JF, Pinder M, Tornieporth N, Carton C, Vigneron L, Milligan P, et al. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS, S\/SBAS2 in semi-immune adults in the Gambia. Am J Trop Med Hyg. 1999;61(6):865\u20138.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"8419_CR41","first-page":"52","volume":"16","author":"OO Latunji","year":"2018","unstructured":"Latunji OO, Akinyemi OO. Factors influencing health-seeking behaviour among civil servants in Ibadan. Nigeria Ann Ib Postgrad Med. 2018;16(1):52\u201360.","journal-title":"Nigeria Ann Ib Postgrad Med"},{"issue":"2","key":"8419_CR42","doi-asserted-by":"publisher","first-page":"446","DOI":"10.4269\/ajtmh.21-0362","volume":"106","author":"I Hossain","year":"2021","unstructured":"Hossain I, Hill P, Bottomley C, Jasseh M, Bojang K, Kaira M, et al. Healthcare seeking and access to care for pneumonia, sepsis, meningitis, and malaria in rural Gambia. Am J Trop Med Hyg. 2021;106(2):446\u201353.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"8419_CR43","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12889-023-15493-2","volume":"23","author":"B Terefe","year":"2023","unstructured":"Terefe B, Mulat B, Shitu K, Assimamaw NT. Individual and community level factors associated with medical treatment-seeking behavior for childhood diarrhea among the Gambian mothers: evidence from the Gambian demographic and health survey data, 2019\/2020. BMC Public Health. 2023;23(1):579.","journal-title":"BMC Public Health"},{"key":"8419_CR44","unstructured":"World Health Organization. Medical Product Alert N\u00b06\/2022: Substandard (contaminated) paediatric medicines: World Health Organization; [18 March 2024]. Available from: https:\/\/www.who.int\/news\/item\/05-10-2022-medical-product-alert-n-6-2022-substandard-(contaminated)-paediatric-medicines."},{"key":"8419_CR45","unstructured":"World Health Organization. Guidelines for Registration of Traditional Medicines in the African Region WHO Africa [21 Feb 2024]. Available from: https:\/\/www.afro.who.int\/publications\/guidelines-registration-traditional-medicines-african-region."},{"key":"8419_CR46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12936-015-0687-2","volume":"14","author":"S O\u2019Neill","year":"2015","unstructured":"O\u2019Neill S, Gryseels C, Dierickx S, Mwesigwa J, Okebe J, d\u2019Alessandro U, Peeters GK. Foul wind, spirits and witchcraft: illness conceptions and health-seeking behaviour for malaria in the Gambia. Malar J. 2015;14:167.","journal-title":"Malar J"},{"key":"8419_CR47","doi-asserted-by":"crossref","unstructured":"Okaiyeto K, Oguntibeju OO. African herbal medicines: adverse effects and cytotoxic potentials with different therapeutic applications. Int J Environ Res Public Health. 2021;18(11).","DOI":"10.3390\/ijerph18115988"},{"issue":"10","key":"8419_CR48","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1046\/j.1440-1746.2000.02349.x","volume":"15","author":"S Chitturi","year":"2000","unstructured":"Chitturi S, Farrell GC. Herbal hepatotoxicity: an expanding but poorly defined problem. J Gastroenterol Hepatol. 2000;15(10):1093\u20139.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"8419_CR49","first-page":"91","volume":"21","author":"S Kadiri","year":"1992","unstructured":"Kadiri S, Ogunlesi A, Osinfade K, Akinkugbe OO. The causes and course of acute tubular necrosis in Nigerians. Afr J Med Med Sci. 1992;21(1):91\u20136.","journal-title":"Afr J Med Med Sci"},{"issue":"21","key":"8419_CR50","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1056\/NEJMoa2214924","volume":"388","author":"FC Haidara","year":"2023","unstructured":"Haidara FC, Umesi A, Sow SO, Ochoge M, Diallo F, Imam A, et al. Meningococcal ACWYX conjugate vaccine in 2-to-29-year-olds in Mali and Gambia. N Engl J Med. 2023;388(21):1942\u201355.","journal-title":"N Engl J Med"},{"issue":"1","key":"8419_CR51","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1186\/s13063-022-06493-5","volume":"23","author":"I Adigweme","year":"2022","unstructured":"Adigweme I, Akpalu E, Yisa M, Donkor S, Jarju LB, Danso B, et al. Study protocol for a phase 1\/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-na\u00efve infants (9 to 10 months) in the Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1\/2 Age De-escalation Trial]. Trials. 2022;23(1):775.","journal-title":"Trials"},{"issue":"2","key":"8419_CR52","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.vaccine.2019.08.072","volume":"38","author":"E Clarke","year":"2020","unstructured":"Clarke E, Bashorun AO, Okoye M, Umesi A, Badjie Hydara M, Adigweme I, et al. Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in the Gambia-results of a phase 1\/2 randomized, double-blinded, controlled trial. Vaccine. 2020;38(2):399\u2013410.","journal-title":"Vaccine"},{"issue":"5","key":"8419_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-000895","volume":"3","author":"PB James","year":"2018","unstructured":"James PB, Wardle J, Steel A, Adams J. Traditional, complementary and alternative medicine use in Sub-Saharan Africa: a systematic review. BMJ Glob Health. 2018;3(5): e000895.","journal-title":"BMJ Glob Health"},{"issue":"5","key":"8419_CR54","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0277-9536(90)90094-9","volume":"31","author":"S Pacqu\u00e9-Margolis","year":"1990","unstructured":"Pacqu\u00e9-Margolis S, Pacqu\u00e9 M, Dukuly Z, Boateng J, Taylor HR. Application of the verbal autopsy during a clinical trial. Soc Sci Med. 1990;31(5):585\u201391.","journal-title":"Soc Sci Med"},{"issue":"9","key":"8419_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003814","volume":"18","author":"RF Breiman","year":"2021","unstructured":"Breiman RF, Blau DM, Mutevedzi P, Akelo V, Mandomando I, Ogbuanu IU, et al. Postmortem investigations and identification of multiple causes of child deaths: an analysis of findings from the Child Health and Mortality Prevention Surveillance (CHAMPS) network. PLoS Med. 2021;18(9): e1003814.","journal-title":"PLoS Med"},{"key":"8419_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106489","volume":"107","author":"F Jiang","year":"2021","unstructured":"Jiang F, Zhang R, Guan Q, Mu Q, He P, Ye X, et al. Immunogenicity and safety of a live attenuated varicella vaccine in children 1\u201312 years of age: a randomized, blinded, controlled, non-inferiority phase 3 clinical trial. Contemp Clin Trials. 2021;107: 106489.","journal-title":"Contemp Clin Trials"},{"issue":"11","key":"8419_CR57","doi-asserted-by":"publisher","DOI":"10.2196\/28874","volume":"23","author":"SL Laursen","year":"2021","unstructured":"Laursen SL, Helweg-J\u00f8rgensen S, Langergaard A, S\u00f8ndergaard J, S\u00f8rensen SS, Mathiasen K, et al. Mobile diary app versus paper-based diary cards for patients with borderline personality disorder: economic evaluation. J Med Internet Res. 2021;23(11): e28874.","journal-title":"J Med Internet Res"},{"key":"8419_CR58","unstructured":"Mitsch JF. Bordering on national language varieties: political and linguistic borders in the Wolof of Senegal and the Gambia: The Ohio State University; 2016."},{"issue":"1","key":"8419_CR59","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12936-021-03732-z","volume":"20","author":"A Fehr","year":"2021","unstructured":"Fehr A, Nieto-Sanchez C, Muela J, Jaiteh F, Ceesay O, Maneh E, et al. From informed consent to adherence: factors influencing involvement in mass drug administration with ivermectin for malaria elimination in The Gambia. Malar J. 2021;20(1):198.","journal-title":"Malar J"},{"key":"8419_CR60","unstructured":"World Health Organization. Good Participatory Practice [30 March 2024]. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov\/solidarity-trial-of-covid-19-vaccines\/good-participatory-practices#:~:text=Good%20Participatory%20Practice%20for%20Emerging%20Pathogens%20(GPP%2DEP)%3A%20a,emerging%20and%20re%2Demerging%20pathogens."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08419-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08419-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08419-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T15:06:47Z","timestamp":1725289607000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08419-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8419"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08419-9","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"31 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"579"}}